Navigation Links
Frost & Sullivan Lauds Aesku.Diagnostics For Providing an Overall Analysis Platform For a Wide Range of Autoimmune Complications
Date:3/3/2009

LONDON, March 3 /PRNewswire/ -- Based on its recent analysis of the autoimmune disease diagnostics markets, Frost & Sullivan recognizes Aesku.Diagnostics with the 2008 European Frost & Sullivan Product Line Strategy Award for its consistent approach towards product development. It has anticipated and catered to the needs in bio-marker identification, offered versatile immunoassay systems, extended research capabilities as well as delivered unprecedented sensitivity and exceptional performance.

(Logo: http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO)

In just eight years of its existence, Aesku.Diagnostics has acquired several antigen and therapy patents and has become a recognised name in the autoimmune diagnostics market in more than 80 countries. It has earned a solid reputation in the market for launching over 140 different products, catering to autoimmune diagnostics and laying equal emphasis on all the major disease sectors under the autoimmune disease diagnostic space.

"Its products fall under two major brands namely, AESKULISA(R) {enzyme-linked immunosorbent assays (ELISA) kits} and AESKUSLIDES(R) (immunofluorescence slide panels)," says Frost & Sullivan Suraj Ramanathan. "The AESKU tests are developed based on human recombinant antigens or native antigens (conformational epitopes) depending on the optimal clinical correlation."

ELISA kits are more popular for autoimmune diagnosis; the company provides more than 100 CE marked kits incorporating human recombinant antigens synthesized in-house to assure maximum sensitivity and specificity. The kits can be used for diagnosing rheumatology, thrombosis, gastroenterology, vasculitis, thyroid, diabetes, hepatology and other rare autoimmune complications. While its 30-30-30 test format can be used with most commercially available automated test platf
'/>"/>

SOURCE Frost & Sullivan
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Frost & Sullivan Lauds Veran Medical for its IG4 Plug-n-Play Navigation System
2. Frost & Sullivan Says, Rising Awareness Boosts High Acuity Areas Monitoring Systems Market in Eastern Europe
3. Frost & Sullivan Awards to Celebrate Healthcare Excellence
4. Market for Niche Blockbusters Promises an Attractive Future for Large Pharmaceutical Companies, Indicates Frost & Sullivan
5. Frost & Sullivan: The Brazilian Municipal Water and Wastewater Treatment Market Set to Double Within the Next Seven Years
6. Frost & Sullivan: Novel Diagnostics Methods Driving the European Cancer IVD Market Towards Early Detection and Prevention
7. Frost & Sullivan Recognizes WCC for Its Unique Multimodal Platform
8. Frost & Sullivan Recognizes Horphags Pioneering R&D Efforts in Health Ingredients
9. Frost & Sullivan: Australian Pharmaceuticals and Life Sciences IT Market Is Still Growing
10. Frost & Sullivan Recognizes Strategic Healthcare Programs for Best Practices in Focused Innovation
11. Frost & Sullivan Says, Innovative Therapies Needed to Deal With the Rapid Spread of Cancer in Europe
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... (PRWEB) November 26, 2014 The city ... water shortages, is moving forward with a plan to ... water.* Radio host Sharon Kleyne supports the San Diego ... Water Management” (TWM). According to Kleyne, by recycling water ... import new water could be greatly reduced. (Spagat, E, ...
(Date:11/26/2014)... 2014 GI for Life announced today, ... in prices of their popular nutritional supplements: ColoVite ... . Discounts of 40% will be offered for ... Life’s proprietary ColoVite supplement is a scientifically formulated vitamin ... health. One easy-to-take colon vitamin with ALL the nutrients ...
(Date:11/26/2014)... (PRWEB) November 26, 2014 Call 866-997-4948 ... requirements or email the details on sales(at)researchmoz(dot)us , ... and drug discovery market 2014" with deep study of ... the result of high blood sugar. The global glucose ... linked to the growing number of diabetics in the ...
(Date:11/26/2014)... News Facts , Lexmark’s ... RSNA 2014 in Chicago. The company will demonstrate ... images, photos, videos and documents found throughout the ... learn more about these innovative medical content management ... initiatives – that enable more informed clinical decisions, ...
(Date:11/26/2014)... TUESDAY, Nov. 25, 2014 (HealthDay News) -- Teens ... likely to abuse those drugs than other teens, ... the need to conduct substance abuse assessments on ... researchers said. "Prescribers and parents don,t realize ... a professor at the University of Michigan School ...
Breaking Medicine News(10 mins):Health News:Global fresh water advocate supports San Diego wastewater recycling plan 2Health News:Global fresh water advocate supports San Diego wastewater recycling plan 3Health News:GI For Life Slashes Prices by 40% on Liposomal Vitamin D3 and ColoVite Colon Health Formula for a Limited Time 2Health News:Latest Report on Diabetes Market 2014 - Global Market Size, Share, Trends and Forecast by Researchmoz.us 2Health News:Latest Report on Diabetes Market 2014 - Global Market Size, Share, Trends and Forecast by Researchmoz.us 3Health News:Perceptive Software to Demonstrate New Medical Content Management Features and Capabilities at RSNA 2014 2Health News:Perceptive Software to Demonstrate New Medical Content Management Features and Capabilities at RSNA 2014 3Health News:Teens Given Anxiety, Sleep Meds May Be at Risk for Drug Abuse 2
... found a way to curb hunger, rev up energy ... of a brain enzyme may curb appetite and boost ... a new study. , Prolylcarboxypeptidase (PRCP) regulates the ... hunger while revving up the body,s energy levels. If ...
... , The National Comprehensive Cancer Network ... the Comparative Effectiveness of health care technologies in cancer care. This ... Effectiveness in Cancer Care to be held in December 2009 , ... The National Comprehensive Cancer Network (NCCN) ...
... , , , , ... Cryo-Cell International, Inc. (OTC Bulletin Board: CCEL), ... innovation today announced a research and development collaboration agreement with nationally ... Research Institute LLC in Tamarac, FL. The partnership will allow Dr. ...
... , , RONKONKOMA, N.Y., July 22 NBTY, ... a leading global manufacturer and marketer of nutritional supplements, today announced ... the United Kingdom by the provisional findings of the Competition Commission. ... on or before September 3, 2009. , , ...
... , BOSTON, July 22 Don,t want a mediocre funeral ... Boston area options. , , "There are people ... even know they have a choice about how to proceed. You can educate ... to the fastest place they can, a funeral home. The funeral homes, though, ...
... ... announced today the formation of their Dentistry Council of Advisors (DCA). The DCA will include ... will help shape the direction of Dentra solutions to dental practices, labs, schools, manufacturers and ... satisfaction. , ...
Cached Medicine News:Health News:NCCN Will Convene National Policy Summit on Comparative Effectiveness in Cancer Care 2Health News:NCCN Will Convene National Policy Summit on Comparative Effectiveness in Cancer Care 3Health News:Cryo-Cell Announces C'elle(SM) Research and Development Collaboration for Chronic Wound Healing Management 2Health News:Cryo-Cell Announces C'elle(SM) Research and Development Collaboration for Chronic Wound Healing Management 3Health News:Cryo-Cell Announces C'elle(SM) Research and Development Collaboration for Chronic Wound Healing Management 4Health News:Cryo-Cell Announces C'elle(SM) Research and Development Collaboration for Chronic Wound Healing Management 5Health News:NBTY Acquisition of Julian Graves Unconditionally Cleared 2Health News:NBTY Acquisition of Julian Graves Unconditionally Cleared 3Health News:NBTY Acquisition of Julian Graves Unconditionally Cleared 4Health News:NBTY Acquisition of Julian Graves Unconditionally Cleared 5Health News:The Boston Funeral Guide Is 'Live' 2Health News:Dentra™ Announces Dentistry Council of Advisors 2Health News:Dentra™ Announces Dentistry Council of Advisors 3
(Date:11/26/2014)... Colo. , Nov. 25, 2014 /PRNewswire/ ... ) today announced that its Chief Executive ... at the following upcoming conferences.  The public ... through webcasts on the Array BioPharma website:  ... December 3, 2014Time:1:30 p.m.  Eastern Time Location: ...
(Date:11/26/2014)... OAKS, Calif. and LONDON , ... ) and AstraZeneca (NYSE: AZN ) today announced ... evaluating two doses of brodalumab in more than 1,800 patients ... with both Stelara ® (ustekinumab) and placebo at week ... brodalumab weight-based analysis group were each shown to be superior ...
(Date:11/26/2014)... and HERZLIYA PITUACH, Israel, Nov. 25, 2014 ... or "the Company"), a clinical stage biopharmaceutical company ... targeted therapeutics for the treatment of inflammatory diseases ... previously announced underwritten public offering of 3,450,000 units, ... the Company,s common stock, par value $0.0001 per ...
Breaking Medicine Technology:Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 3Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 4Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 5Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 6Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 7Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 8Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 9Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 10Immune Pharmaceuticals Inc. Announces Closing Of Public Offering Of Common Stock And Warrants 2Immune Pharmaceuticals Inc. Announces Closing Of Public Offering Of Common Stock And Warrants 3Immune Pharmaceuticals Inc. Announces Closing Of Public Offering Of Common Stock And Warrants 4Immune Pharmaceuticals Inc. Announces Closing Of Public Offering Of Common Stock And Warrants 5
... successful,KB2115 Phase II study meets primary objectives. The ... KB2115 in patients with dyslipidemia,has been successfully completed. ... respect to a broad range of parameters,reflecting effects ... thyroid hormone receptor (TR) is a key regulator ...
... the Congress of the European Hematology,Association, SAN ... , a biopharmaceutical company developing patient-specific,active immunotherapies ... from a Phase 2 clinical trial of ... (NHL). The data were,reported at the Congress ...
Cached Medicine Technology:Karo Bio Announces Sucessfule Phase II Results of KB2115 2Karo Bio Announces Sucessfule Phase II Results of KB2115 3Favrille Announces Data From Phase 2 Clinical Trial of FavId for,Indolent B-Cell Non-Hodgkin's Lymphoma in Europe 2Favrille Announces Data From Phase 2 Clinical Trial of FavId for,Indolent B-Cell Non-Hodgkin's Lymphoma in Europe 3
... providers can code the charge while completing a ... while away from office, both directly feeding the ... an Encounter Form/Superbill, data entry can be done ... patient payments are posted by reflecting open item ...
The CH 2000 Cardiac Diagnostic system is a fully featured stress testing system that can include Microvolt T-Wave Alternans (MTWA) testing capability as an add-on feature. , ,Interfaces with Tra...
The HearTwave system is the original stand-alone Microvolt T-Wave Alternans (MTWA) testing platform....
... features 4 precisely angled 64° mirrors to ... anterior chamber angle with slight rotation. ... element) provides a stable platform during laser ... mirror lens provides a complete view of ...
Medicine Products: